Celsion Corporation (NASDAQ:CLSN)
Shares of Celsion Corporation (NASDAQ:CLSN) fell 5.2% after the oncology drug development company reported financial results for the three and nine months ended September 30, 2017. A net loss for the two periods appears to have spooked the market, fuelling a sell-off of the stock.
Following Tuesday’s sell-off, Celsion Corporation (NASDAQ:CLSN) is at risk of dropping to this year’s lows as it continues to trade in a strong downtrend. The stock has shed more than 50% in market value since the start of the year as investors continue to question the company’s long-term prospects.
However, data compiled by Zacks Investment Research indicates that two analyst firms currently rate the stock as a ‘strong buy’ amidst the growing short interest. Despite disappointing financial results, analysts are forecasting a 76.6% year over year increase in earnings. The analysts also expect earnings to grow by 48.4% next year.
For the quarter ended September 30, 2017, Celsion Corporation (NASDAQ:CLSN) reported a net loss of (-$5.7) million or (-$0.70) a share compared to a net loss of (-$6.4) million reported last year. The company attributes the decrease to a tighter clinical development focus coupled with lower operational expenses. Net loss for the first nine months came in at (-$16.1) million compared to (-$16.7) million as of last year.
Celsion Pipeline Development
During the quarter Celsion Corporation (NASDAQ:CLSN) recognized deemed dividends totaling $0.4 million with regards to multiple agreements with certain warrant holders. The company also made important milestones in the development of its lead clinical programs and capital infusion of $38 million to help drive the development efforts.
Celsion Corporation (NASDAQ:CLSN) is currently working on ThermoDox, its proprietary heat-activated liposomal encapsulation currently in Phase III for the treatment of primary liver cancer. The company’s immunotherapy program consisting of GEN-1 is currently in Phase 1 development as a localized treatment for Ovarian Cancer.
“We believe that we now have sufficient capital to complete enrollment of our Phase III OPTIMA Study and through the first efficacy analysis expected in the first quarter of 2019. Further, we expect that our current funds will allow us to make substantial progress in our open-label, randomized, 86 patient Phase I/II study of GEN-1 in newly diagnosed stage III and IV ovarian cancer patients,” said CEO, Michael Tardugno.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.